Menu
Legislation being marked up in the U.S. House today could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP). | Shutterstock

House Set To Act on Bill that Could Result in Higher Medicaid Rebates and 340B Discounts

In Federal, Legislative20 Views Tom Mirga
The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content